Enanta Pharmaceuticals Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Enanta Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Enanta Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Enanta Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.15. The biotechnology company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $25.05 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 12.21% and a negative net margin of 78.57%. The company's quarterly revenue was down 27.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share.
View Enanta Pharmaceuticals' earnings history.

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENTA stock has decreased by 22.0% and is now trading at $41.30.
View which stocks have been most impacted by COVID-19.

7 brokers have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $30.00 to $107.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $65.29 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Enanta Pharmaceuticals include Karuna Therapeutics (KRTX), Cerevel Therapeutics (CERE), Turning Point Therapeutics (TPTX), Agios Pharmaceuticals (AGIO), Nektar Therapeutics (NKTR), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), PTC Therapeutics (PTCT), Taro Pharmaceutical Industries (TARO), Cryoport (CYRX), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Pacira BioSciences (PCRX), Sage Therapeutics (SAGE) and ATA (ATAI).
View all of ENTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%).
View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $41.30.

Enanta Pharmaceuticals has a market capitalization of $834.05 million and generates $122.47 million in revenue each year. The biotechnology company earns $-36,170,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

Enanta Pharmaceuticals employs 141 workers across the globe.

The official website for Enanta Pharmaceuticals is www.enanta.com.

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]